Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Solomon

Showing results (151-160 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutationsAdel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Glomerular Diseases|February 13, 2024
FSGS Recurrence Collaboration: Report of a SymposiumDebbie S Gipson, Chia-Shi Wang, Eloise Salmon, et al.
Archives of Pathology & Laboratory Medicine|January 23, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
The Journal of Molecular Diagnostics : JMD|February 6, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
Pageof 19

Showing results (151-160 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutationsAdel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Glomerular Diseases|February 13, 2024
FSGS Recurrence Collaboration: Report of a SymposiumDebbie S Gipson, Chia-Shi Wang, Eloise Salmon, et al.
Archives of Pathology & Laboratory Medicine|January 23, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
The Journal of Molecular Diagnostics : JMD|February 6, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.
Pageof 19